ARDS

Aridis Pharmaceuticals Inc. (ARDS) | Rumor.io

Aridis Pharmaceuticals

ARDS

Attention (50-day avg)0%

Attention rank (50-day avg)#4,241

Bullish sentiment (50-day avg)0%

Price to earnings ratio-0

Market capitalization4.5K

Earnings per share-0.01

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-30.4M

Social

What share of all stock conversation is about ARDS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Jul 19

ARDIS Pharmaceuticals, Inc. has been delisted from Robinhood, but is still trading normally on NASDAQ.
The company has received positive news lately, which has contributed to its recent rally.
The current share price of ARDS is around $0.28, with volume increasing in the last couple of days.

Generated by AI

Sentiment

Of the messages about ARDS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	0% -43.14
Bearish	—	—	—	100% +43.14

Bullish· Jul 18

The European Medicines Agency has approved the clinical study design and a single confirmatory Phase 3 study of AR-301, leading to a 30.46% price increase.
ARDS stock has a low price, making it a good opportunity to buy the dip and potentially double in value.
The company's 80% insider ownership and potential $1.20 price target by late August indicate a strong foundation for future growth.

Bearish· Jul 18

ARDIS Pharmaceuticals, Inc. (ARDS) has been accused of intentionally releasing a PR to mislead investors, knowing they would be delisted.
The company's stock price has dropped significantly after a pump, with some investors experiencing substantial losses.
ARDIS' delisting and subsequent move to the OTC market has led to a sharp decline in the stock price, with some investors calling it a "bad joke" and a "trip bottom bounce".

Generated by AI

Topics

Of the messages about ARDS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	—
Announcements	—	—	—	—
Controversies	—	—	—	—
Earnings	—	—	—	—
Macro	—	—	—	—
Technical Analysis	—	—	—	—

Announcements· Jul 12

Ardis Pharmaceuticals' AR-301 Monoclonal Antibody received FDA's Qualified Infectious Diseases Product (QIDP) designation.
The QIDP designation may increase the buyout price or partnership deal for Ardis, and the company is trying to align with a large pharma company, possibly AstraZeneca.
Ardis' cash situation is a concern, with a $8 million loan to be repaid by early 2024 and limited funds for clinical development, leading to speculation about potential sales or outlicensing of the company or its drugs.

Technical Analysis· Dec 21

$ARDS is close to breaking out, with some analysts predicting a move to the upside.
The stock is showing major divergence, indicating mass accumulation and a potential explosive move.
$ARDS has broken above its 200-day SMA and is holding above it, with some analysts predicting a clean bounce to $4 and a potential retest of $6.50.

Generated by AI

Community

Of the messages about ARDS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	65.96%
Newcomers	100%	100%	100%	34.04%

Also Discussed

Investors talking about ARDS also mention

#	Name	Attention
1	Tokyo Lifestyle Co., Ltd. American Depositary SharesTKLF	0%0
2	PBLA - Panbela Therapeutics, Inc.	——
3	Nuvectis Pharma, Inc.NVCT	0%0
4	Biofrontera Inc.BFRI	0%0
5	DNAY - Codex DNA, Inc.	——
6	FGI Industries Ltd.FGI	0%0
7	Society Pass IncorporatedSOPA	0%0
8	Minerva Surgical Inc.UTRS	0%0
9	Ensysce Biosciences, Inc. Common StockENSC	0%0
10	FRLN - Freeline Therapeutics Holdings plc	——

Aridis Pharmaceuticals Inc.

Healthcare
Biotechnology

Aridis Pharmaceuticals Inc. is a late-stage biopharmaceutical company focused on discovering and developing targeted immunotherapies using fully human monoclonal antibodies to treat life-threatening infectious diseases. Its lead product candidate, AR-301, is a fully human immunoglobulin G1 monoclonal antibody that has completed Phase III pivotal trials for lung infections caused by Staphylococcus aureus alpha-toxin and is being developed as an adjunctive therapy with standard-of-care antibiotics for hospital-acquired and ventilator-associated pneumonia. The company is also advancing AR-320, a monoclonal antibody targeting S. aureus alpha-toxin for infections from methicillin-resistant and susceptible strains; AR-501, an inhaled gallium citrate formulation in Phase 1/2a trials for chronic lung infections in cystic fibrosis patients; and AR-101, a human IgM monoclonal antibody in Phase II trials against Pseudomonas aeruginosa lipopolysaccharide serotype O11. Aridis Pharmaceuticals Inc. operates in the biotechnology sector, emphasizing novel anti-infective solutions for hospital and ventilator-related bacterial infections. Founded in 2003 and headquartered in Los Gatos, California, it remains dedicated to addressing unmet needs in infectious disease treatment.

Website

Location

983 University Avenue

Los Gatos, CA, 95032

United States

Social

What share of all stock conversation is about ARDS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Jul 19

ARDIS Pharmaceuticals, Inc. has been delisted from Robinhood, but is still trading normally on NASDAQ.
The company has received positive news lately, which has contributed to its recent rally.
The current share price of ARDS is around $0.28, with volume increasing in the last couple of days.

Generated by AI

Sentiment

Of the messages about ARDS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	0% -43.14
Bearish	—	—	—	100% +43.14

Bullish· Jul 18

The European Medicines Agency has approved the clinical study design and a single confirmatory Phase 3 study of AR-301, leading to a 30.46% price increase.
ARDS stock has a low price, making it a good opportunity to buy the dip and potentially double in value.
The company's 80% insider ownership and potential $1.20 price target by late August indicate a strong foundation for future growth.

Bearish· Jul 18

ARDIS Pharmaceuticals, Inc. (ARDS) has been accused of intentionally releasing a PR to mislead investors, knowing they would be delisted.
The company's stock price has dropped significantly after a pump, with some investors experiencing substantial losses.
ARDIS' delisting and subsequent move to the OTC market has led to a sharp decline in the stock price, with some investors calling it a "bad joke" and a "trip bottom bounce".

Generated by AI

Topics

Of the messages about ARDS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	—
Announcements	—	—	—	—
Controversies	—	—	—	—
Earnings	—	—	—	—
Macro	—	—	—	—
Technical Analysis	—	—	—	—

Announcements· Jul 12

Ardis Pharmaceuticals' AR-301 Monoclonal Antibody received FDA's Qualified Infectious Diseases Product (QIDP) designation.
The QIDP designation may increase the buyout price or partnership deal for Ardis, and the company is trying to align with a large pharma company, possibly AstraZeneca.
Ardis' cash situation is a concern, with a $8 million loan to be repaid by early 2024 and limited funds for clinical development, leading to speculation about potential sales or outlicensing of the company or its drugs.

Technical Analysis· Dec 21

$ARDS is close to breaking out, with some analysts predicting a move to the upside.
The stock is showing major divergence, indicating mass accumulation and a potential explosive move.
$ARDS has broken above its 200-day SMA and is holding above it, with some analysts predicting a clean bounce to $4 and a potential retest of $6.50.

Generated by AI

Community

Of the messages about ARDS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	65.96%
Newcomers	100%	100%	100%	34.04%

Aridis Pharmaceuticals

Social

Jul 19

Sentiment

Bullish· Jul 18

Bearish· Jul 18

Topics

Announcements· Jul 12

Technical Analysis· Dec 21

Community

Also Discussed

Aridis Pharmaceuticals Inc.

Company Information

Location

Also Discussed

Social

Jul 19

Sentiment

Bullish· Jul 18

Bearish· Jul 18

Topics

Announcements· Jul 12

Technical Analysis· Dec 21

Community